This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations 4 Q&As
1 Citations
Facts about Transcription factor E2F2.
E2F2 binds specifically to RB1 in a cell-cycle dependent manner. .
Human | |
---|---|
Gene Name: | E2F2 |
Uniprot: | Q14209 |
Entrez: | 1870 |
Belongs to: |
---|
E2F/DP family |
E2F transcription factor 2; E2F2; E2F-2; E2F-2transcription factor E2F2
Mass (kDA):
47.506 kDA
Human | |
---|---|
Location: | 1p36.12 |
Sequence: | 1; NC_000001.11 (23505696..23531250, complement) |
Highest level of expression is found in placenta, low levels are found in lung. Found as well in many immortalized cell lines derived from tumor samples.
Nucleus.
You've found the right place if you're looking to find a high-quality antibody which recognizes the E2F2 transcription element. This antibody's Specificity, Validation and Applications will be discussed. Boster Bio validates the antibodies. Boster Bio rewards scientists who review its products with product credits or rewards. These rewards are open for scientists from all over the world.
Several studies have shown that overexpression of the transcription factor E2F3 has a negative correlation with tumor cell apoptosis. E2F3 is present in both squamous-cell lung cancer and head-and neck cancer. It plays a significant role in the development of the disease. E2F3 is also negatively correlated with Bcl-2 (an apoptotic regulator) and Bax (which may play a part in tumor cell proliferation).
Antibodies against transcription factor E2F2 are available from many suppliers. The target gene, known as E2F-2, is located in human cells and is reported to have a mass of 47.5 kilobaltons. The gene name also includes the names of canine, fly, and mouse orthologs. Various studies have shown that E2F2 protein is expressed most abundantly in the integument and fat body of mammals.
Boster Bio used a cell line and fresh tissue lysate for validation to create a high-sensitivity ELISA Kit. The lysate had to be heated at 95°C (for 10 minutes) and transferred onto a PVDF-coated membrane. After cooling, the membrane was sealed with 5% skimmed Milk in TBST. The membrane was then incubated for 24 hours with primary antibodies to E2F3 (or Bcl-2) in the same blocking buffer.
Studies have also been done on E2F3 and lung cancer. These studies show that this antibody can be used to predict the outcome of patients with NSCLC. Studies have shown that the transcription factor has a significant role in NSCLC progression. FDA approved the use this antibody for cancer patients. A dedicated webpage has been created by the company to showcase this antibody.
The expression levels can determine the specificity or non-specificity of the E2F2 gene marker. E2F2 promotes transcription of many genes that are vital for DNA synthesis and entry into S phase. The cell's capacity to replicate DNA depends on its expression level. E2F1 can be damaged before mitosis, and DNA damage can promote it. These alterations are believed to be associated with poor prognosis for patients with cancer.
E2F2 deletion in Myc-driven tumors significantly increased metastasis. It is therefore important for regulating gene expression related to metastasis. This is in contrast to other mouse models of breast carcinoma, where the E2F2 gene was lost and metastatic capacity was reduced. This suggests that E2F transcription factor plays a central role for oncogene-specific genes.
The Cancer Genome Atlas project found the PTPRD mutation. This discovery has a larger significance. While the gene PTPRD is a novel candidate, it was found to be frequently mutated in breast cancer and hypermethylated in late-stage tumors. It appears that PTPRD plays a role in the metastasis of breast cancer cells when combined with the loss of E2F2.
Although the PTPRD is not a direct transcriptional target of E2F2, it functions through its relationship with Myc. In fact, perturbations in STAT3 levels have been linked with alterations in c-Myc. The E2F2-Myc complex has a c-Myc binding site, which could potentially help distinguish between tumors and normal brain cells.
E2F2 also promotes DNA repairs. E2F1 or E2F2 can be transcriptionally active. However further research is needed in order to determine which genes E2F2 targets. If a specific cell type responds to a particular gene, the E2F marker will be induced. These proteins have a profound impact on our lives.
Complex regulation of E2F1 is achieved by the checkpoint. As these proteins are involved with DNA replication stress, the differential regulation of this gene may be affected by DNA damage intensity and type. This may lead patients to experience different outcomes. The E2F2 gene, however, is an important part of the checkpoint system. This gene is important for cancer treatment. E2F2 may also be used to identify tumor cells.
The validation of the E2F2 marker has been carried out using a number of studies, including gene expression profiling. In these studies, E2F1 and E2F2 were found to be significantly higher in gastric cancer than in normal cells, which suggests that these genes may be potential therapeutic targets. Additionally, E2F1/2/3/5/8 showed a positive correlation with clinical cancer stage and tumor grade. Patients with high mRNA expressions of E2F1/2/3/4/5/5 and E2F6/7/8 had better overall survival (OS). The mutation rate for this gene was also high.
Further research is required to determine the role played by E2F2 during CRC. This marker has been shown to regulate B-Myb-mediated signaling pathways. However, it is unclear if E2F2 can be directly targeted with the BRD4 inhibition. This suggests that suppression may occur later. Validation of the E2F2 marker requires additional data. This includes additional studies in larger patient groups.
Numerous studies have shown a positive correlation of E2F2 and B-Myb in colorectal carcinoma. In addition, these two genes interact, directly transactivating each other. They also form reciprocal feed-forward transcription loops. Both B-Myb as well as E2F2 are crucial for activating ERK and AKT signaling pathways during colorectal carcinoma. To validate the E2F2 marker's accuracy, a clinical trial is required to establish its validity.
The E2F2 gene was found significantly to be correlated with eight core genes of human HCC cells. A heatmap showing the correlation analysis results between E2F2 gene and each gene was created. These values were then expressed as Pearson correlation coefficients. The BRD4 gene also showed a significant correlation with E2F2 and these two genes. These studies support validation of E2F2's gene.
E2F2 also plays a key role in tumorigenesis. It regulates PI3K/Akt/mTOR-mediated autophagy and can be a useful biomarker of GC. Further research is needed to examine the role of E2F2 in tumor immunity. There are many reasons that the E2F2 marker should not be invalidated.
Recent research has shown that E2F2 marker expression in blood cells is strongly correlated with the presence or absence of CD8+ T cells, neutrophils, macrophages, and B cells in human cancer tissues. The E2F2 indicator could offer insight into PAAD patients' immune system. Further research is needed to better understand PAAD's molecular mechanisms and to develop new immunotherapies. E2F2 may have many clinical applications, but it needs more experimental research to confirm its clinical use.
In cell culture, studies showed that the E2F2 marker could be used to identify cells in an arrest or quiescent condition. Furthermore, knockdown of this protein increased cell migration through the transwell insert membrane. E2F2 knockdown in PC12 cells inhibits cell growth, a type NGF-induced neuron. However, it is not applicable in animal models.
E2F2 was found to reduce metastasis in human breast cancer. This result was consistent and in line with results from a study on mice that suggested that E2F2 may affect the PTPRD Signaling axis. Further research is needed to understand the mechanism of E2F2 regulation within cancer cells. These encouraging findings aside, further research will be required to determine the role played by the E2F2 marker during the disease process.
E2F2 dysregulation can be associated with cancer of various types. The E2F2 protein is involved with cell proliferation and differentiation. It can also affect apoptosis as well as senescence. These cancers are very rare but research has shown a poor survival rate for E2Fs. E2F2 can also be found in postmitotic neural cells. It may play an important role in promoting neuronal apoptosis.
PMID: 8246995 by Ivey-Hoyle M., et al. Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F.
PMID: 16360038 by Rubin S.M., et al. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release.
*More publications can be found for each product on its corresponding product page